-
1 . Academic Journal
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
- 저자
- by Bardymova, Tatiana; Barrientos Perez, Margarita; Bethin, Kathleen; Bjornstad, Petter; Bondar, Irina, et al.
- 소스
- In The Lancet Diabetes & Endocrinology March 2023 11(3):169-181
-
7 . Periodical
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
- 저자
- by Laffel, Lori M; Danne, Thomas; Klingensmith, Georgeanna J; Tamborlane, William V; Willi, Steven, et al.
- 소스
- The Lancet Diabetes & Endocrinology; March 2023, Vol. 11 Issue: 3 p169-181, 13p